Upajak β Upadacitinib 15 mg Tablets
6145β΄
7023β΄
-13%
Upajak 15 mg (Upadacitinib) is a state-of-the-art JAK inhibitor and a generic equivalent to Rinvoq. It is a selective Janus kinase 1 (JAK1) inhibitor designed to disrupt inflammatory signals inside the cells responsible for autoimmune conditions.
Manufacturer: Everest Pharmaceuticals (Bangladesh). β οΈ Note: Contains 30 extended-release tablets per bottle. The drug offers high efficacy for patients seeking remission from severe arthritis and dermatitis symptoms.
Key Features:
- β Mechanism of Action: Inhibits the JAK1 enzyme, effectively blocking the inflammatory pathways that damage joints and skin.
- β Convenience: Extended-release formulation ensures consistent drug levels in the body with just one daily dose.
- β Accessibility: This high-quality generic from Everest provides a cost-effective alternative to expensive brand-name therapies.
Prescribed by rheumatologists, dermatologists, or gastroenterologists for:
- πΉ Rheumatoid Arthritis (RA): Moderate to severe active RA in patients who have had an inadequate response to DMARDs (e.g., methotrexate).
- πΉ Psoriatic Arthritis (PsA): To reduce joint pain, swelling, and stiffness.
- πΉ Ankylosing Spondylitis (AS).
- πΉ Atopic Dermatitis: For refractory moderate to severe eczema.
- πΉ Ulcerative Colitis & Crohn's Disease.
Sales Unit: 1 Bottle (30 Tablets of 15 mg).
β οΈ ADMINISTRATION GUIDELINES:
- Standard Dosage: 15 mg (1 tablet) once daily. Should be taken at approximately the same time each day.
- How to take: Swallow the tablet whole with water. Can be taken with or without food.
- β IMPORTANT: Do NOT chew, crush, or break the tablet, as this affects the extended-release mechanism.
- Missed Dose: Take as soon as remembered unless it is almost time for the next dose. Do not double the dose.
- β Active Serious Infections: Active tuberculosis (TB), sepsis, or opportunistic infections must be ruled out before starting.
- Severe hepatic impairment.
- Pregnancy and breastfeeding (potential risk to the fetus).
- Children under 12 years or body weight less than 40 kg.
- Hypersensitivity to Upadacitinib.
Regular medical monitoring is advised. Potential side effects:
- π¦ Infections: Upper respiratory tract infections (common cold, sore throat).
- π Skin: Acne, potential reactivation of herpes zoster (shingles).
- π©Έ Labs: Elevations in lipids (cholesterol), liver enzymes, or decrease in neutrophils.
- β οΈ Rare but Serious: Increased risk of thrombosis (blood clots) in high-risk patients.
100% original product
Delivery across Ukraine
Alternatives
View all in category
Similar products
Customer reviews
What Customers Say
No reviews yet
Your review can be the first!